Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity

AIDS. 1997 May;11(6):819-20.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Avipoxvirus
  • Consumer Product Safety
  • Double-Blind Method
  • Genetic Vectors
  • HIV Antibodies / blood
  • HIV Core Protein p24 / blood
  • HIV Envelope Protein gp160 / genetics
  • HIV Envelope Protein gp160 / therapeutic use*
  • HIV Infections / blood
  • HIV Infections / immunology
  • HIV Infections / therapy*
  • HIV Infections / virology
  • Humans
  • Immunogenetics
  • Immunotherapy, Active*
  • Recombination, Genetic
  • Vaccines, Synthetic*
  • Viral Load
  • Viral Vaccines*

Substances

  • ALVAC vaccine
  • HIV Antibodies
  • HIV Core Protein p24
  • HIV Envelope Protein gp160
  • Vaccines, Synthetic
  • Viral Vaccines